MX2022010118A - Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19). - Google Patents
Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19).Info
- Publication number
- MX2022010118A MX2022010118A MX2022010118A MX2022010118A MX2022010118A MX 2022010118 A MX2022010118 A MX 2022010118A MX 2022010118 A MX2022010118 A MX 2022010118A MX 2022010118 A MX2022010118 A MX 2022010118A MX 2022010118 A MX2022010118 A MX 2022010118A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- detection
- covid
- proteins
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 208000025721 COVID-19 Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940023143 protein vaccine Drugs 0.000 abstract 1
- 230000000405 serological effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Abstract
La presente divulgación hace referencia a un sistema de alivio para la detección, prevención y tratamiento efectivos de la COVID-19 que incluye (1) ensayos de diagnóstico serológico para la detección de infección viral y vigilancia epidemiológica, (2) construcciones inmunogénicas de péptidos de precisión alta dirigidos al sitio para la prevención de la infección por SARS-CoV-2, (3) terapias antivirales basadas en receptores para el tratamiento de la enfermedad en pacientes infectados y (4) una vacuna de proteína de diseño que contiene S1-RBD-sFc. El sistema de alivio descrito utiliza secuencias de aminoácidos de proteínas del SARS-CoV-2, así como receptores humanos para el diseño y la fabricación de péptidos antigénicos de SARS-CoV-2 óptimos, construcciones inmunogénicas de péptidos, construcciones inmunogénicas de proteínas derivadas de CHO, proteínas ACE2 derivadas de CHO de acción prolongada y formulaciones de estas, para el diagnóstico, las vacunas y las terapias antivirales para la detección, la prevención y el tratamiento de la COVID-19.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062978596P | 2020-02-19 | 2020-02-19 | |
US202062990382P | 2020-03-16 | 2020-03-16 | |
US202063027290P | 2020-05-19 | 2020-05-19 | |
US202063118596P | 2020-11-25 | 2020-11-25 | |
PCT/US2021/018855 WO2021168305A1 (en) | 2020-02-19 | 2021-02-19 | Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010118A true MX2022010118A (es) | 2022-09-05 |
Family
ID=77392273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010118A MX2022010118A (es) | 2020-02-19 | 2021-02-19 | Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19). |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230109393A1 (es) |
EP (1) | EP4107180A4 (es) |
JP (1) | JP2023515800A (es) |
KR (1) | KR20220144829A (es) |
AU (1) | AU2021222039A1 (es) |
BR (1) | BR112022016574A2 (es) |
CA (1) | CA3172443A1 (es) |
MX (1) | MX2022010118A (es) |
TW (1) | TWI818236B (es) |
WO (1) | WO2021168305A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113087777B (zh) * | 2020-04-17 | 2023-05-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及用该蛋白制备的疫苗 |
CN115803091A (zh) * | 2020-05-22 | 2023-03-14 | 福迈康股份公司 | Ace2-fc融合蛋白及其用途 |
WO2021254868A1 (en) * | 2020-06-19 | 2021-12-23 | Sciensano | Multiplex sars-cov-2 immunoassay |
WO2022013609A1 (en) * | 2020-07-13 | 2022-01-20 | Immunovaccine Technologies, Inc. | Sars-cov-2 vaccine compositions and methods of preparation and use |
EP4228697A1 (en) | 2020-10-16 | 2023-08-23 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
WO2022090469A2 (en) * | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
CN112852666A (zh) * | 2021-01-19 | 2021-05-28 | 新疆河润水业有限责任公司 | 一种微生物菌剂的制备方法及采用微生物菌剂制备的微生物肥料 |
WO2023034933A1 (en) * | 2021-09-02 | 2023-03-09 | Nonigenex, Inc. | Methods and systems for assessing adaptive immunity to coronavirus |
CN113717258B (zh) * | 2021-09-03 | 2023-09-29 | 郑州安图生物工程股份有限公司 | 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒 |
WO2023044397A1 (en) * | 2021-09-15 | 2023-03-23 | The Board Of The Trustees Of The University Of Illinois | Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof |
CN113769080B (zh) * | 2021-09-17 | 2023-04-07 | 清华大学 | 多肽免疫偶联物及其应用 |
TW202334198A (zh) * | 2021-10-12 | 2023-09-01 | 聯亞生技開發股份有限公司 | 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物 |
WO2023069461A2 (en) * | 2021-10-19 | 2023-04-27 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
WO2023079001A1 (en) * | 2021-11-03 | 2023-05-11 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
GB202117821D0 (en) * | 2021-12-09 | 2022-01-26 | Univ Edinburgh | A method of providing peptides |
WO2023154781A2 (en) * | 2022-02-09 | 2023-08-17 | Vaxxinity, Inc. | Sars-cov-2 vaccine for the prevention and treatment of coronavirus disease (covid-19) |
WO2024011163A1 (en) * | 2022-07-06 | 2024-01-11 | Georgia State University Research Foundation, Inc. | Coronavirus vaccines and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004321500A1 (en) * | 2003-09-29 | 2006-05-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunoglobulins with potent and broad antiviral activity |
US20050214748A1 (en) * | 2003-11-12 | 2005-09-29 | Wang Chang Y | Peptide-based diagnostic reagents for SARS |
CA2569142A1 (en) * | 2004-06-02 | 2005-12-22 | New York Blood Center | Sars vaccines and methods to produce highly potent antibodies |
CN101522208A (zh) * | 2005-02-08 | 2009-09-02 | 纽约血库公司 | 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体 |
MX2008014710A (es) * | 2006-05-19 | 2009-02-12 | Amgen Inc | Anticuerpos para coronavirus del sars. |
CA2996996A1 (en) * | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
CN106380517B (zh) * | 2016-10-28 | 2019-07-16 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种对中东呼吸综合征冠状病毒具有中和活性的小分子抗体及其应用 |
US11696948B2 (en) * | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
RU2709659C1 (ru) * | 2018-09-06 | 2019-12-19 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты) |
WO2021156490A2 (en) * | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
-
2021
- 2021-02-19 TW TW110105685A patent/TWI818236B/zh active
- 2021-02-19 US US17/801,055 patent/US20230109393A1/en active Pending
- 2021-02-19 AU AU2021222039A patent/AU2021222039A1/en active Pending
- 2021-02-19 BR BR112022016574A patent/BR112022016574A2/pt unknown
- 2021-02-19 KR KR1020227031724A patent/KR20220144829A/ko active Search and Examination
- 2021-02-19 JP JP2022549659A patent/JP2023515800A/ja active Pending
- 2021-02-19 MX MX2022010118A patent/MX2022010118A/es unknown
- 2021-02-19 CA CA3172443A patent/CA3172443A1/en active Pending
- 2021-02-19 EP EP21756390.7A patent/EP4107180A4/en active Pending
- 2021-02-19 WO PCT/US2021/018855 patent/WO2021168305A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR20220144829A (ko) | 2022-10-27 |
WO2021168305A1 (en) | 2021-08-26 |
BR112022016574A2 (pt) | 2023-02-14 |
CA3172443A1 (en) | 2021-08-26 |
TW202144384A (zh) | 2021-12-01 |
TWI818236B (zh) | 2023-10-11 |
JP2023515800A (ja) | 2023-04-14 |
US20230109393A1 (en) | 2023-04-06 |
EP4107180A1 (en) | 2022-12-28 |
EP4107180A4 (en) | 2024-05-08 |
AU2021222039A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010118A (es) | Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19). | |
Staats et al. | Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN (A). | |
YAMAMOTO et al. | Experimental vaccine protection against feline immunodeficiency virus | |
US11918645B2 (en) | Vaccines against hepatitis B virus | |
LUBECK et al. | Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration | |
EP0328403B1 (en) | Synthetic peptides related to the HIV-GP120-env-protein, and their use | |
AU570929B2 (en) | Broad spectrum influenza antisera | |
TWI620574B (zh) | ***合成胜肽緊急疫苗 | |
JP2023529413A (ja) | Tlr7アゴニストにカップリングする新規コロナウイルスポリペプチドワクチンおよびその適用 | |
Thapar et al. | Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM) | |
AU8091694A (en) | Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics | |
EA004802B1 (ru) | МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ | |
Aaskov et al. | Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409) | |
Fast et al. | Human trials of experimental AIDS vaccines | |
CN106102769A (zh) | 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途 | |
Britt et al. | Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice | |
WO1989002277A3 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
WO1992005800A1 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
Weidinger et al. | Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model | |
Payne et al. | Localization of conserved and variable antigenic domains of equine infectious anemia virus envelope glycoproteins using recombinant env-encoded protein fragments produced in Escherichia coli | |
Zhu et al. | A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice | |
NO20006457L (no) | Vaksine-indusert hepatitt B viral stamme og anvendelser derav | |
Poovorawan et al. | Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects | |
Vafai | Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine | |
CN101628118A (zh) | 流感复合多表位dna疫苗及其应用 |